JavaScript NENÍ povolen !

Prosím povolte JavaScript.

* Zobrazit nápovědu

Reset

MeSH: faktor Xa-terapeutické užití

63 záznamů v Medvik Filtry

Článek

Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage

Connolly, Stuart J
Autor Connolly, Stuart J ORCID From the Population Health Research Institute, McMaster University, Hamilton, ON (S.J.C., M.S., M.C., A.T., T.K., L.X., K.T., A.S.), and the Departments of Clinical Neurosciences and Radiology, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, AB (A.M.D.) - both in Canada Guy's and St. Thomas' Hospital, King's College London (A.T.C.), and Imperial College (R.V.), London, NIHR Biomedical Research Centre and College of Life Sciences, University of Leicester, Leicester (T.G.R.), and Alexion Pharmaceuticals UK, Uxbridge (A.L.) - all in the United Kingdom the Second Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland (A.C.) the Department of Clinical Sciences Lund, Neurology, Lund University, and the Department of Neurology, Skåne University Hospital, Lund (A.G.L.), and AstraZeneca Biopharmaceuticals Research and Development, Late-stage Development, Cardiovascular, Renal, and Metabolism, Gothenburg (A.H., P.L., M.K., E.E.) - all in Sweden Vall d'Hebron University Hospital, Barcelona (C.A.M.) Semmelweis University, Budapest, Hungary (D.B.) Sapienza University of Rome, Rome (D. Toni) the Department of Neurology, Inselspital University Hospital and University of Bern, Bern, Switzerland (D.J.S.) Rambam Health Care Campus, Technion, Israel Institute of Technology, Haifa (D. Tanne) the Department of Neurology, Oslo University Hospital, and the Norwegian Air Ambulance Foundation - both in Oslo (E.C.S.) the Second Department of Neurology, National and Kapodistrian University of Athens, "Attikon" University Hospital, Athens (G.T.) Copenhagen University Hospital, Bispebjerg Hospital, Copenhagen (H.C.) the Department of Medicine 1, Division "Thrombosis and Hemostasis," University Hospital Dresden, Dresden (J.B.-W.), Alfried Krupp Krankenhaus, Essen (R.V.), the Department of Neurology and Stroke (S.P.) and the Hertie Institute for Clinical Brain Research (S.P.), Eberhard-Karls University, Tübingen, the Department of Neurology, Universitätsklinikum Erlangen, Erlangen (B.K.), and the Department of Neurology, Heidelberg University Hospital, Heidelberg (C.G.) - all in Germany the Department of Neurology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam (J.M.C.), and Radboud University Medical Center, Nijmegen (S.M.) - both in the Netherlands University Hospitals Leuven, University of Leuven (P.V.), the Department of Neurosciences and Experimental Neurology, KU Leuven (R.L.), and the Department of Neurology, University Hospitals Leuven (R.L.) - all in Leuven, Belgium Bichat Claude-Bernard Hospital, Paris (P.A.) Turku University Hospital, Turku, Finland (R.O.R.) Tomas Bata Regional Hospital, Zlín, Czech Republic (R.M.) Dell Medical School, University of Texas, Austin, and the University of Houston, Houston (T.J.M.) University of Porto, Porto, Portugal (V.T.-C.) and Hospital of St. John of God, Sigmund Freud University, Medical Faculty, Vienna (W.L.)
Sharma, Mukul
Autor Sharma, Mukul From the Population Health Research Institute, McMaster University, Hamilton, ON (S.J.C., M.S., M.C., A.T., T.K., L.X., K.T., A.S.), and the Departments of Clinical Neurosciences and Radiology, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, AB (A.M.D.) - both in Canada Guy's and St. Thomas' Hospital, King's College London (A.T.C.), and Imperial College (R.V.), London, NIHR Biomedical Research Centre and College of Life Sciences, University of Leicester, Leicester (T.G.R.), and Alexion Pharmaceuticals UK, Uxbridge (A.L.) - all in the United Kingdom the Second Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland (A.C.) the Department of Clinical Sciences Lund, Neurology, Lund University, and the Department of Neurology, Skåne University Hospital, Lund (A.G.L.), and AstraZeneca Biopharmaceuticals Research and Development, Late-stage Development, Cardiovascular, Renal, and Metabolism, Gothenburg (A.H., P.L., M.K., E.E.) - all in Sweden Vall d'Hebron University Hospital, Barcelona (C.A.M.) Semmelweis University, Budapest, Hungary (D.B.) Sapienza University of Rome, Rome (D. Toni) the Department of Neurology, Inselspital University Hospital and University of Bern, Bern, Switzerland (D.J.S.) Rambam Health Care Campus, Technion, Israel Institute of Technology, Haifa (D. Tanne) the Department of Neurology, Oslo University Hospital, and the Norwegian Air Ambulance Foundation - both in Oslo (E.C.S.) the Second Department of Neurology, National and Kapodistrian University of Athens, "Attikon" University Hospital, Athens (G.T.) Copenhagen University Hospital, Bispebjerg Hospital, Copenhagen (H.C.) the Department of Medicine 1, Division "Thrombosis and Hemostasis," University Hospital Dresden, Dresden (J.B.-W.), Alfried Krupp Krankenhaus, Essen (R.V.), the Department of Neurology and Stroke (S.P.) and the Hertie Institute for Clinical Brain Research (S.P.), Eberhard-Karls University, Tübingen, the Department of Neurology, Universitätsklinikum Erlangen, Erlangen (B.K.), and the Department of Neurology, Heidelberg University Hospital, Heidelberg (C.G.) - all in Germany the Department of Neurology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam (J.M.C.), and Radboud University Medical Center, Nijmegen (S.M.) - both in the Netherlands University Hospitals Leuven, University of Leuven (P.V.), the Department of Neurosciences and Experimental Neurology, KU Leuven (R.L.), and the Department of Neurology, University Hospitals Leuven (R.L.) - all in Leuven, Belgium Bichat Claude-Bernard Hospital, Paris (P.A.) Turku University Hospital, Turku, Finland (R.O.R.) Tomas Bata Regional Hospital, Zlín, Czech Republic (R.M.) Dell Medical School, University of Texas, Austin, and the University of Houston, Houston (T.J.M.) University of Porto, Porto, Portugal (V.T.-C.) and Hospital of St. John of God, Sigmund Freud University, Medical Faculty, Vienna (W.L.)
Cohen, Alexander T
Autor Cohen, Alexander T From the Population Health Research Institute, McMaster University, Hamilton, ON (S.J.C., M.S., M.C., A.T., T.K., L.X., K.T., A.S.), and the Departments of Clinical Neurosciences and Radiology, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, AB (A.M.D.) - both in Canada Guy's and St. Thomas' Hospital, King's College London (A.T.C.), and Imperial College (R.V.), London, NIHR Biomedical Research Centre and College of Life Sciences, University of Leicester, Leicester (T.G.R.), and Alexion Pharmaceuticals UK, Uxbridge (A.L.) - all in the United Kingdom the Second Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland (A.C.) the Department of Clinical Sciences Lund, Neurology, Lund University, and the Department of Neurology, Skåne University Hospital, Lund (A.G.L.), and AstraZeneca Biopharmaceuticals Research and Development, Late-stage Development, Cardiovascular, Renal, and Metabolism, Gothenburg (A.H., P.L., M.K., E.E.) - all in Sweden Vall d'Hebron University Hospital, Barcelona (C.A.M.) Semmelweis University, Budapest, Hungary (D.B.) Sapienza University of Rome, Rome (D. Toni) the Department of Neurology, Inselspital University Hospital and University of Bern, Bern, Switzerland (D.J.S.) Rambam Health Care Campus, Technion, Israel Institute of Technology, Haifa (D. Tanne) the Department of Neurology, Oslo University Hospital, and the Norwegian Air Ambulance Foundation - both in Oslo (E.C.S.) the Second Department of Neurology, National and Kapodistrian University of Athens, "Attikon" University Hospital, Athens (G.T.) Copenhagen University Hospital, Bispebjerg Hospital, Copenhagen (H.C.) the Department of Medicine 1, Division "Thrombosis and Hemostasis," University Hospital Dresden, Dresden (J.B.-W.), Alfried Krupp Krankenhaus, Essen (R.V.), the Department of Neurology and Stroke (S.P.) and the Hertie Institute for Clinical Brain Research (S.P.), Eberhard-Karls University, Tübingen, the Department of Neurology, Universitätsklinikum Erlangen, Erlangen (B.K.), and the Department of Neurology, Heidelberg University Hospital, Heidelberg (C.G.) - all in Germany the Department of Neurology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam (J.M.C.), and Radboud University Medical Center, Nijmegen (S.M.) - both in the Netherlands University Hospitals Leuven, University of Leuven (P.V.), the Department of Neurosciences and Experimental Neurology, KU Leuven (R.L.), and the Department of Neurology, University Hospitals Leuven (R.L.) - all in Leuven, Belgium Bichat Claude-Bernard Hospital, Paris (P.A.) Turku University Hospital, Turku, Finland (R.O.R.) Tomas Bata Regional Hospital, Zlín, Czech Republic (R.M.) Dell Medical School, University of Texas, Austin, and the University of Houston, Houston (T.J.M.) University of Porto, Porto, Portugal (V.T.-C.) and Hospital of St. John of God, Sigmund Freud University, Medical Faculty, Vienna (W.L.)
Demchuk, Andrew M
Autor Demchuk, Andrew M From the Population Health Research Institute, McMaster University, Hamilton, ON (S.J.C., M.S., M.C., A.T., T.K., L.X., K.T., A.S.), and the Departments of Clinical Neurosciences and Radiology, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, AB (A.M.D.) - both in Canada Guy's and St. Thomas' Hospital, King's College London (A.T.C.), and Imperial College (R.V.), London, NIHR Biomedical Research Centre and College of Life Sciences, University of Leicester, Leicester (T.G.R.), and Alexion Pharmaceuticals UK, Uxbridge (A.L.) - all in the United Kingdom the Second Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland (A.C.) the Department of Clinical Sciences Lund, Neurology, Lund University, and the Department of Neurology, Skåne University Hospital, Lund (A.G.L.), and AstraZeneca Biopharmaceuticals Research and Development, Late-stage Development, Cardiovascular, Renal, and Metabolism, Gothenburg (A.H., P.L., M.K., E.E.) - all in Sweden Vall d'Hebron University Hospital, Barcelona (C.A.M.) Semmelweis University, Budapest, Hungary (D.B.) Sapienza University of Rome, Rome (D. Toni) the Department of Neurology, Inselspital University Hospital and University of Bern, Bern, Switzerland (D.J.S.) Rambam Health Care Campus, Technion, Israel Institute of Technology, Haifa (D. Tanne) the Department of Neurology, Oslo University Hospital, and the Norwegian Air Ambulance Foundation - both in Oslo (E.C.S.) the Second Department of Neurology, National and Kapodistrian University of Athens, "Attikon" University Hospital, Athens (G.T.) Copenhagen University Hospital, Bispebjerg Hospital, Copenhagen (H.C.) the Department of Medicine 1, Division "Thrombosis and Hemostasis," University Hospital Dresden, Dresden (J.B.-W.), Alfried Krupp Krankenhaus, Essen (R.V.), the Department of Neurology and Stroke (S.P.) and the Hertie Institute for Clinical Brain Research (S.P.), Eberhard-Karls University, Tübingen, the Department of Neurology, Universitätsklinikum Erlangen, Erlangen (B.K.), and the Department of Neurology, Heidelberg University Hospital, Heidelberg (C.G.) - all in Germany the Department of Neurology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam (J.M.C.), and Radboud University Medical Center, Nijmegen (S.M.) - both in the Netherlands University Hospitals Leuven, University of Leuven (P.V.), the Department of Neurosciences and Experimental Neurology, KU Leuven (R.L.), and the Department of Neurology, University Hospitals Leuven (R.L.) - all in Leuven, Belgium Bichat Claude-Bernard Hospital, Paris (P.A.) Turku University Hospital, Turku, Finland (R.O.R.) Tomas Bata Regional Hospital, Zlín, Czech Republic (R.M.) Dell Medical School, University of Texas, Austin, and the University of Houston, Houston (T.J.M.) University of Porto, Porto, Portugal (V.T.-C.) and Hospital of St. John of God, Sigmund Freud University, Medical Faculty, Vienna (W.L.)
Członkowska, Anna
Autor Członkowska, Anna From the Population Health Research Institute, McMaster University, Hamilton, ON (S.J.C., M.S., M.C., A.T., T.K., L.X., K.T., A.S.), and the Departments of Clinical Neurosciences and Radiology, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, AB (A.M.D.) - both in Canada Guy's and St. Thomas' Hospital, King's College London (A.T.C.), and Imperial College (R.V.), London, NIHR Biomedical Research Centre and College of Life Sciences, University of Leicester, Leicester (T.G.R.), and Alexion Pharmaceuticals UK, Uxbridge (A.L.) - all in the United Kingdom the Second Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland (A.C.) the Department of Clinical Sciences Lund, Neurology, Lund University, and the Department of Neurology, Skåne University Hospital, Lund (A.G.L.), and AstraZeneca Biopharmaceuticals Research and Development, Late-stage Development, Cardiovascular, Renal, and Metabolism, Gothenburg (A.H., P.L., M.K., E.E.) - all in Sweden Vall d'Hebron University Hospital, Barcelona (C.A.M.) Semmelweis University, Budapest, Hungary (D.B.) Sapienza University of Rome, Rome (D. Toni) the Department of Neurology, Inselspital University Hospital and University of Bern, Bern, Switzerland (D.J.S.) Rambam Health Care Campus, Technion, Israel Institute of Technology, Haifa (D. Tanne) the Department of Neurology, Oslo University Hospital, and the Norwegian Air Ambulance Foundation - both in Oslo (E.C.S.) the Second Department of Neurology, National and Kapodistrian University of Athens, "Attikon" University Hospital, Athens (G.T.) Copenhagen University Hospital, Bispebjerg Hospital, Copenhagen (H.C.) the Department of Medicine 1, Division "Thrombosis and Hemostasis," University Hospital Dresden, Dresden (J.B.-W.), Alfried Krupp Krankenhaus, Essen (R.V.), the Department of Neurology and Stroke (S.P.) and the Hertie Institute for Clinical Brain Research (S.P.), Eberhard-Karls University, Tübingen, the Department of Neurology, Universitätsklinikum Erlangen, Erlangen (B.K.), and the Department of Neurology, Heidelberg University Hospital, Heidelberg (C.G.) - all in Germany the Department of Neurology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam (J.M.C.), and Radboud University Medical Center, Nijmegen (S.M.) - both in the Netherlands University Hospitals Leuven, University of Leuven (P.V.), the Department of Neurosciences and Experimental Neurology, KU Leuven (R.L.), and the Department of Neurology, University Hospitals Leuven (R.L.) - all in Leuven, Belgium Bichat Claude-Bernard Hospital, Paris (P.A.) Turku University Hospital, Turku, Finland (R.O.R.) Tomas Bata Regional Hospital, Zlín, Czech Republic (R.M.) Dell Medical School, University of Texas, Austin, and the University of Houston, Houston (T.J.M.) University of Porto, Porto, Portugal (V.T.-C.) and Hospital of St. John of God, Sigmund Freud University, Medical Faculty, Vienna (W.L.)
Lindgren, Arne G
Autor Lindgren, Arne G From the Population Health Research Institute, McMaster University, Hamilton, ON (S.J.C., M.S., M.C., A.T., T.K., L.X., K.T., A.S.), and the Departments of Clinical Neurosciences and Radiology, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, AB (A.M.D.) - both in Canada Guy's and St. Thomas' Hospital, King's College London (A.T.C.), and Imperial College (R.V.), London, NIHR Biomedical Research Centre and College of Life Sciences, University of Leicester, Leicester (T.G.R.), and Alexion Pharmaceuticals UK, Uxbridge (A.L.) - all in the United Kingdom the Second Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland (A.C.) the Department of Clinical Sciences Lund, Neurology, Lund University, and the Department of Neurology, Skåne University Hospital, Lund (A.G.L.), and AstraZeneca Biopharmaceuticals Research and Development, Late-stage Development, Cardiovascular, Renal, and Metabolism, Gothenburg (A.H., P.L., M.K., E.E.) - all in Sweden Vall d'Hebron University Hospital, Barcelona (C.A.M.) Semmelweis University, Budapest, Hungary (D.B.) Sapienza University of Rome, Rome (D. Toni) the Department of Neurology, Inselspital University Hospital and University of Bern, Bern, Switzerland (D.J.S.) Rambam Health Care Campus, Technion, Israel Institute of Technology, Haifa (D. Tanne) the Department of Neurology, Oslo University Hospital, and the Norwegian Air Ambulance Foundation - both in Oslo (E.C.S.) the Second Department of Neurology, National and Kapodistrian University of Athens, "Attikon" University Hospital, Athens (G.T.) Copenhagen University Hospital, Bispebjerg Hospital, Copenhagen (H.C.) the Department of Medicine 1, Division "Thrombosis and Hemostasis," University Hospital Dresden, Dresden (J.B.-W.), Alfried Krupp Krankenhaus, Essen (R.V.), the Department of Neurology and Stroke (S.P.) and the Hertie Institute for Clinical Brain Research (S.P.), Eberhard-Karls University, Tübingen, the Department of Neurology, Universitätsklinikum Erlangen, Erlangen (B.K.), and the Department of Neurology, Heidelberg University Hospital, Heidelberg (C.G.) - all in Germany the Department of Neurology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam (J.M.C.), and Radboud University Medical Center, Nijmegen (S.M.) - both in the Netherlands University Hospitals Leuven, University of Leuven (P.V.), the Department of Neurosciences and Experimental Neurology, KU Leuven (R.L.), and the Department of Neurology, University Hospitals Leuven (R.L.) - all in Leuven, Belgium Bichat Claude-Bernard Hospital, Paris (P.A.) Turku University Hospital, Turku, Finland (R.O.R.) Tomas Bata Regional Hospital, Zlín, Czech Republic (R.M.) Dell Medical School, University of Texas, Austin, and the University of Houston, Houston (T.J.M.) University of Porto, Porto, Portugal (V.T.-C.) and Hospital of St. John of God, Sigmund Freud University, Medical Faculty, Vienna (W.L.)
Molina, Carlos A
Autor Molina, Carlos A From the Population Health Research Institute, McMaster University, Hamilton, ON (S.J.C., M.S., M.C., A.T., T.K., L.X., K.T., A.S.), and the Departments of Clinical Neurosciences and Radiology, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, AB (A.M.D.) - both in Canada Guy's and St. Thomas' Hospital, King's College London (A.T.C.), and Imperial College (R.V.), London, NIHR Biomedical Research Centre and College of Life Sciences, University of Leicester, Leicester (T.G.R.), and Alexion Pharmaceuticals UK, Uxbridge (A.L.) - all in the United Kingdom the Second Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland (A.C.) the Department of Clinical Sciences Lund, Neurology, Lund University, and the Department of Neurology, Skåne University Hospital, Lund (A.G.L.), and AstraZeneca Biopharmaceuticals Research and Development, Late-stage Development, Cardiovascular, Renal, and Metabolism, Gothenburg (A.H., P.L., M.K., E.E.) - all in Sweden Vall d'Hebron University Hospital, Barcelona (C.A.M.) Semmelweis University, Budapest, Hungary (D.B.) Sapienza University of Rome, Rome (D. Toni) the Department of Neurology, Inselspital University Hospital and University of Bern, Bern, Switzerland (D.J.S.) Rambam Health Care Campus, Technion, Israel Institute of Technology, Haifa (D. Tanne) the Department of Neurology, Oslo University Hospital, and the Norwegian Air Ambulance Foundation - both in Oslo (E.C.S.) the Second Department of Neurology, National and Kapodistrian University of Athens, "Attikon" University Hospital, Athens (G.T.) Copenhagen University Hospital, Bispebjerg Hospital, Copenhagen (H.C.) the Department of Medicine 1, Division "Thrombosis and Hemostasis," University Hospital Dresden, Dresden (J.B.-W.), Alfried Krupp Krankenhaus, Essen (R.V.), the Department of Neurology and Stroke (S.P.) and the Hertie Institute for Clinical Brain Research (S.P.), Eberhard-Karls University, Tübingen, the Department of Neurology, Universitätsklinikum Erlangen, Erlangen (B.K.), and the Department of Neurology, Heidelberg University Hospital, Heidelberg (C.G.) - all in Germany the Department of Neurology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam (J.M.C.), and Radboud University Medical Center, Nijmegen (S.M.) - both in the Netherlands University Hospitals Leuven, University of Leuven (P.V.), the Department of Neurosciences and Experimental Neurology, KU Leuven (R.L.), and the Department of Neurology, University Hospitals Leuven (R.L.) - all in Leuven, Belgium Bichat Claude-Bernard Hospital, Paris (P.A.) Turku University Hospital, Turku, Finland (R.O.R.) Tomas Bata Regional Hospital, Zlín, Czech Republic (R.M.) Dell Medical School, University of Texas, Austin, and the University of Houston, Houston (T.J.M.) University of Porto, Porto, Portugal (V.T.-C.) and Hospital of St. John of God, Sigmund Freud University, Medical Faculty, Vienna (W.L.)
Bereczki, Daniel
Autor Bereczki, Daniel ORCID From the Population Health Research Institute, McMaster University, Hamilton, ON (S.J.C., M.S., M.C., A.T., T.K., L.X., K.T., A.S.), and the Departments of Clinical Neurosciences and Radiology, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, AB (A.M.D.) - both in Canada Guy's and St. Thomas' Hospital, King's College London (A.T.C.), and Imperial College (R.V.), London, NIHR Biomedical Research Centre and College of Life Sciences, University of Leicester, Leicester (T.G.R.), and Alexion Pharmaceuticals UK, Uxbridge (A.L.) - all in the United Kingdom the Second Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland (A.C.) the Department of Clinical Sciences Lund, Neurology, Lund University, and the Department of Neurology, Skåne University Hospital, Lund (A.G.L.), and AstraZeneca Biopharmaceuticals Research and Development, Late-stage Development, Cardiovascular, Renal, and Metabolism, Gothenburg (A.H., P.L., M.K., E.E.) - all in Sweden Vall d'Hebron University Hospital, Barcelona (C.A.M.) Semmelweis University, Budapest, Hungary (D.B.) Sapienza University of Rome, Rome (D. Toni) the Department of Neurology, Inselspital University Hospital and University of Bern, Bern, Switzerland (D.J.S.) Rambam Health Care Campus, Technion, Israel Institute of Technology, Haifa (D. Tanne) the Department of Neurology, Oslo University Hospital, and the Norwegian Air Ambulance Foundation - both in Oslo (E.C.S.) the Second Department of Neurology, National and Kapodistrian University of Athens, "Attikon" University Hospital, Athens (G.T.) Copenhagen University Hospital, Bispebjerg Hospital, Copenhagen (H.C.) the Department of Medicine 1, Division "Thrombosis and Hemostasis," University Hospital Dresden, Dresden (J.B.-W.), Alfried Krupp Krankenhaus, Essen (R.V.), the Department of Neurology and Stroke (S.P.) and the Hertie Institute for Clinical Brain Research (S.P.), Eberhard-Karls University, Tübingen, the Department of Neurology, Universitätsklinikum Erlangen, Erlangen (B.K.), and the Department of Neurology, Heidelberg University Hospital, Heidelberg (C.G.) - all in Germany the Department of Neurology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam (J.M.C.), and Radboud University Medical Center, Nijmegen (S.M.) - both in the Netherlands University Hospitals Leuven, University of Leuven (P.V.), the Department of Neurosciences and Experimental Neurology, KU Leuven (R.L.), and the Department of Neurology, University Hospitals Leuven (R.L.) - all in Leuven, Belgium Bichat Claude-Bernard Hospital, Paris (P.A.) Turku University Hospital, Turku, Finland (R.O.R.) Tomas Bata Regional Hospital, Zlín, Czech Republic (R.M.) Dell Medical School, University of Texas, Austin, and the University of Houston, Houston (T.J.M.) University of Porto, Porto, Portugal (V.T.-C.) and Hospital of St. John of God, Sigmund Freud University, Medical Faculty, Vienna (W.L.)
Toni, Danilo
Autor Toni, Danilo From the Population Health Research Institute, McMaster University, Hamilton, ON (S.J.C., M.S., M.C., A.T., T.K., L.X., K.T., A.S.), and the Departments of Clinical Neurosciences and Radiology, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, AB (A.M.D.) - both in Canada Guy's and St. Thomas' Hospital, King's College London (A.T.C.), and Imperial College (R.V.), London, NIHR Biomedical Research Centre and College of Life Sciences, University of Leicester, Leicester (T.G.R.), and Alexion Pharmaceuticals UK, Uxbridge (A.L.) - all in the United Kingdom the Second Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland (A.C.) the Department of Clinical Sciences Lund, Neurology, Lund University, and the Department of Neurology, Skåne University Hospital, Lund (A.G.L.), and AstraZeneca Biopharmaceuticals Research and Development, Late-stage Development, Cardiovascular, Renal, and Metabolism, Gothenburg (A.H., P.L., M.K., E.E.) - all in Sweden Vall d'Hebron University Hospital, Barcelona (C.A.M.) Semmelweis University, Budapest, Hungary (D.B.) Sapienza University of Rome, Rome (D. Toni) the Department of Neurology, Inselspital University Hospital and University of Bern, Bern, Switzerland (D.J.S.) Rambam Health Care Campus, Technion, Israel Institute of Technology, Haifa (D. Tanne) the Department of Neurology, Oslo University Hospital, and the Norwegian Air Ambulance Foundation - both in Oslo (E.C.S.) the Second Department of Neurology, National and Kapodistrian University of Athens, "Attikon" University Hospital, Athens (G.T.) Copenhagen University Hospital, Bispebjerg Hospital, Copenhagen (H.C.) the Department of Medicine 1, Division "Thrombosis and Hemostasis," University Hospital Dresden, Dresden (J.B.-W.), Alfried Krupp Krankenhaus, Essen (R.V.), the Department of Neurology and Stroke (S.P.) and the Hertie Institute for Clinical Brain Research (S.P.), Eberhard-Karls University, Tübingen, the Department of Neurology, Universitätsklinikum Erlangen, Erlangen (B.K.), and the Department of Neurology, Heidelberg University Hospital, Heidelberg (C.G.) - all in Germany the Department of Neurology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam (J.M.C.), and Radboud University Medical Center, Nijmegen (S.M.) - both in the Netherlands University Hospitals Leuven, University of Leuven (P.V.), the Department of Neurosciences and Experimental Neurology, KU Leuven (R.L.), and the Department of Neurology, University Hospitals Leuven (R.L.) - all in Leuven, Belgium Bichat Claude-Bernard Hospital, Paris (P.A.) Turku University Hospital, Turku, Finland (R.O.R.) Tomas Bata Regional Hospital, Zlín, Czech Republic (R.M.) Dell Medical School, University of Texas, Austin, and the University of Houston, Houston (T.J.M.) University of Porto, Porto, Portugal (V.T.-C.) and Hospital of St. John of God, Sigmund Freud University, Medical Faculty, Vienna (W.L.)
Seiffge, David J
Autor Seiffge, David J From the Population Health Research Institute, McMaster University, Hamilton, ON (S.J.C., M.S., M.C., A.T., T.K., L.X., K.T., A.S.), and the Departments of Clinical Neurosciences and Radiology, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, AB (A.M.D.) - both in Canada Guy's and St. Thomas' Hospital, King's College London (A.T.C.), and Imperial College (R.V.), London, NIHR Biomedical Research Centre and College of Life Sciences, University of Leicester, Leicester (T.G.R.), and Alexion Pharmaceuticals UK, Uxbridge (A.L.) - all in the United Kingdom the Second Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland (A.C.) the Department of Clinical Sciences Lund, Neurology, Lund University, and the Department of Neurology, Skåne University Hospital, Lund (A.G.L.), and AstraZeneca Biopharmaceuticals Research and Development, Late-stage Development, Cardiovascular, Renal, and Metabolism, Gothenburg (A.H., P.L., M.K., E.E.) - all in Sweden Vall d'Hebron University Hospital, Barcelona (C.A.M.) Semmelweis University, Budapest, Hungary (D.B.) Sapienza University of Rome, Rome (D. Toni) the Department of Neurology, Inselspital University Hospital and University of Bern, Bern, Switzerland (D.J.S.) Rambam Health Care Campus, Technion, Israel Institute of Technology, Haifa (D. Tanne) the Department of Neurology, Oslo University Hospital, and the Norwegian Air Ambulance Foundation - both in Oslo (E.C.S.) the Second Department of Neurology, National and Kapodistrian University of Athens, "Attikon" University Hospital, Athens (G.T.) Copenhagen University Hospital, Bispebjerg Hospital, Copenhagen (H.C.) the Department of Medicine 1, Division "Thrombosis and Hemostasis," University Hospital Dresden, Dresden (J.B.-W.), Alfried Krupp Krankenhaus, Essen (R.V.), the Department of Neurology and Stroke (S.P.) and the Hertie Institute for Clinical Brain Research (S.P.), Eberhard-Karls University, Tübingen, the Department of Neurology, Universitätsklinikum Erlangen, Erlangen (B.K.), and the Department of Neurology, Heidelberg University Hospital, Heidelberg (C.G.) - all in Germany the Department of Neurology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam (J.M.C.), and Radboud University Medical Center, Nijmegen (S.M.) - both in the Netherlands University Hospitals Leuven, University of Leuven (P.V.), the Department of Neurosciences and Experimental Neurology, KU Leuven (R.L.), and the Department of Neurology, University Hospitals Leuven (R.L.) - all in Leuven, Belgium Bichat Claude-Bernard Hospital, Paris (P.A.) Turku University Hospital, Turku, Finland (R.O.R.) Tomas Bata Regional Hospital, Zlín, Czech Republic (R.M.) Dell Medical School, University of Texas, Austin, and the University of Houston, Houston (T.J.M.) University of Porto, Porto, Portugal (V.T.-C.) and Hospital of St. John of God, Sigmund Freud University, Medical Faculty, Vienna (W.L.)

The New England journal of medicine. 2024 ; 390 (19) : 1745-1755. [pub] 20240516

N Engl J Med
ISSN 1533-4406
Medvik
Zdroj

BACKGROUND: Patients with acute intracerebral hemorrhage who are receiving factor Xa inhibitors have a risk of hematoma expansion. The effect of andexanet alfa, an agent that reverses the effects of factor Xa inhibitors, on hematoma volume expansion has not been well studied. METHODS: We randomly assigned, in a 1:1 ratio, patients who had taken factor Xa inhibitors within 15 hours before having an acute intracerebral hemorrhage to receive andexanet or usual care. The primary end point was hemostatic efficacy, defined by expansion of the hematoma volume by 35% or less at 12 hours after baseline, an increase in the score on the National Institutes of Health Stroke Scale of less than 7 points (scores range from 0 to 42, with higher scores indicating worse neurologic deficit) at 12 hours, and no receipt of rescue therapy between 3 hours and 12 hours. Safety end points were thrombotic events and death. RESULTS: A total of 263 patients were assigned to receive andexanet, and 267 to receive usual care. Efficacy was assessed in an interim analysis that included 452 patients, and safety was analyzed in all 530 enrolled patients. Atrial fibrillation was the most common indication for factor Xa inhibitors. Of the patients receiving usual care, 85.5% received prothrombin complex concentrate. Hemostatic efficacy was achieved in 150 of 224 patients (67.0%) receiving andexanet and in 121 of 228 (53.1%) receiving usual care (adjusted difference, 13.4 percentage points; 95% confidence interval [CI], 4.6 to 22.2; P = 0.003). The median reduction from baseline to the 1-to-2-hour nadir in anti-factor Xa activity was 94.5% with andexanet and 26.9% with usual care (P<0.001). Thrombotic events occurred in 27 of 263 patients (10.3%) receiving andexanet and in 15 of 267 (5.6%) receiving usual care (difference, 4.6 percentage points; 95% CI, 0.1 to 9.2; P = 0.048); ischemic stroke occurred in 17 patients (6.5%) and 4 patients (1.5%), respectively. There were no appreciable differences between the groups in the score on the modified Rankin scale or in death within 30 days. CONCLUSIONS: Among patients with intracerebral hemorrhage who were receiving factor Xa inhibitors, andexanet resulted in better control of hematoma expansion than usual care but was associated with thrombotic events, including ischemic stroke. (Funded by Alexion AstraZeneca Rare Disease and others; ANNEXA-I ClinicalTrials.gov number, NCT03661528.).

Článek online

Nová přímá perorální antikoagulancia - nové molekuly ve výzkumu
[New direct oral anticoagulances - new molecules in research]

Zatloukalová, Anna
Autor Autorita Lékařská fakulta, Centrum epidemiologického výzkumu, Ostravská univerzita Univerzita Palackého Olomouc, Fakulta zdravotnických věd, Univerzita Palackého Olomouc Ústav zdravotnického managementu, Univerzita Palackého Olomouc

Klinická farmakologie a farmacie. 2020 ; 34 (2) : 84-88.

ISSN 1212-7973
Medvik
Zdroj

V současné době nová přímá perorální antikoagulancia (DOAC) postupně nahrazují dosavadní historicky nejčastěji užívaný warfarin. Jedná se o dvě skupiny léčiv přímo inhibující faktor Xa (Xarelto, Eliquis, Lixiana) a trombin (Pradaxa). Nabízí mnohá pozitiva, která ocení i samotní pacienti. Jedná se zejména o odpadnutí nutnosti pravidelné monitorace, minimum lékových a potravinových interakcí či příznivý bezpečnostní profil. Nicméně jako jednu z nevýhod lze vnímat nepřítomnost antidota při předávkování. Své specifické antidotum - Idarucizumab - má v současné době pouze Pradaxa. Ostatní jsou ve vývoji, stejně tak jako nové molekuly samotných antikoagulancií.

Currently, new direct oral anticoagulants (DOAC) are gradually replacing the historically most frequently used warfarin. These are two classes of drugs directly inhibiting factor Xa (Xarelto, Eliquis, Lixiana) and thrombin (Pradaxa). It offers many positives that patients themselves will appreciate. These include, in particular, no need for regular monitoring, minimal drug and food interactions, or afavorable safety profile. However, one of the drawbacks is the absence of antidotes for overdose. Only Pradaxa currently has its specific antidote - Idarucizumab. Others are in development as well as new molecules of anticoagulants themselves.

Článek online

Nová přímá perorální antikoagulancia -nové molekuly ve výzkumu
[New direct oral anticoagulances - new molecules in research]

Zatloukalová, Anna
Autor Autorita Lékařská fakulta, Centrum epidemiologického výzkumu, Ostravská univerzita Univerzita Palackého Olomouc, Fakulta zdravotnických věd, Univerzita Palackého Olomouc Ústav zdravotnického managementu, Univerzita Palackého Olomouc

Praktické lékárenství. 2020 ; 16 (4) : 3-12.

ISSN 1801-2434
Medvik
Zdroj

Článek

Krvácivé komplikace antikoagulační léčby
[Bleeding compliations of anticoagulant therapy]

Kessler, Petr, 1957-
Autor Autorita Oddělení hematologie a transfuziologie, Nemocnice Pelhřimov

Remedia. 2016 ; 26 (5) : 472-475.

ISSN 0862-8947
Medvik
Zdroj

Antikoagulační léčba je neoddělitelně spjata se zvýšeným rizikem krvácivých komplikací. V článku jsou popsány nejvýznamnější příčiny krvácivých komplikací u pacientů léčených nefrakcionovaným heparinem, nízkomolekulárním heparinem, antagonisty vitaminu K, dabigatranem a přímými perorálními inhibitory faktoru Xa včetně mnohočetných lékových interakcí warfarinu. Jsou uvedeny laboratorní testy hemostázy, které mohou být užitečné při určení role antikoagulancií v genezi krvácení. Článek se také zaměřuje na léčbu krvácivých komplikací antikoagulační léčby, shrnuje účinnost i nedostatky antidot dostupných v současné době. Je zdůrazněna role koncentrátů protrombinového komplexu v léčbě krvácivých komplikací u pacientů užívajících warfarin a význam idarucizumabu – specifického antidota dabigatranu –, který se stal v poslední době dostupným v České republice.

The anticoagulant therapy is inseparably accompanied by an increased risk of bleeding complications. The most prominent causes of bleeding complications in patients treated with unfractionated heparin, low molecular weight heparin, vitamin K antagonists, dabigatran and direct oral inhibitors of factor Xa are described in the article, including multiple drug interactions of warfarin. Laboratory tests of haemostasis, which can be useful for determination of the role of anticoagulant drugs in pathogenesis of bleeding, are mentioned. The article also focuses on the management of bleeding complications of anticoagulant therapy, reviewing the effectiveness and limits of antidotes, which are currently available. The role of prothrombin complex concentrates in treatment of bleeding complications in patients taking warfarin is pointed out as well as the importance of idarucizumab – a specific antidote of dabigatran, which became available in Czech Republic recently.

Článek

Řešení urgentních stavů spojených s rizikem krvácení u nemocných užívajících nová perorální antikoagulancia – možnosti ukončení účinku
[Treatment of emergencies associated with bleeding risk in patients taking new oral anticoagulants - options concerning termination of their effect]

Remedia. 2016 ; 26 (2) : 135-140.

ISSN 0862-8947
Medvik
Zdroj

Nová perorální antikoagulancia užívaná v ČR (dabigatran, apixaban, rivaroxaban), která jsou indikována v prevenci systémové embolizace u nevalvulární fibrilace síní a v léčbě tromboembolické nemoci, měla dosud nevýhodu nedostupnosti specifického antidota pro případ vzniku významného krvácení nebo nutnosti urgentního chirurgického výkonu. Od podzimu 2015 již bylo schváleno k použití antidotum pro dabigatran etexilát – idarucizumab, monoklonální protilátka k vyvázání a k inaktivaci léčiva. Přípravek je registrován a dostupný na farmaceutickém trhu. K reverzi účinku xabanů jsou na obzoru dvě antidota – 3. fází klinického hodnocení prochází andexanet alfa, určený jako antidotum xabanů, i ciraparantag (PER977), který působí jako univerzální antagonista antikoagulačního účinku xabanů i heparinů.

New oral anticoagulants prescribed in the Czech Republic (dabigatran, apixaban, rivaroxaban), indicated for prevention of systemic embolization in non valvular atrial fibrillation and for treatment of thromboembolic disease, had a major disadvantage until recently: there was no specific antidote available for their users in cases of significant bleeding or in cases when urgent surgery was needed. During autumn of 2015, antidote for dabigatran exetilate – idarucizumab, a monoclonal antibody capable of binding and inactivation of this drug – was approved for clinical use. It has been registered and became available on the pharmaceutical market. As for the xabans, two antidotes are approaching their approval – andexanet alpha, making its way through phase 3 clinical trials (xaban antidote), and ciraparantag (PER77), acting as a universal antidote of both xabans and heparins.

Článek

Rivaroxaban při fibrilaci síní

Chlumský, Jaromír, 1962-
Autor Autorita Interní klinika 2. LF UK a FNM, Praha

Farmakoterapie. 2014 ; 10 (4) : 413-415.

Farmakoterapie (Praha Print)
ISSN 1801-1209
Medvik
Zdroj

Kniha

Vnitřní lékařství 2014 : XXI. kongres České internistické společnosti ČLS JP : 15.-18.10.2014

Česká internistická společnost ČLS JEP. Sjezd (21. : 2014 : Brno, Česko)
Autor Autorita
Česká internistická společnost ČLS JEP
Autor Autorita

Praha : Axonite CZ, 2014

Axonite review

1. vyd. 26 s. : il. (převážně barev.), 1 portrét ; 30 cm

Článek

Možnosti léčby hluboké žilní trombózy v roce 2014
[Deep vein thrombosis therapy options available in 2014]

Kardiologická revue. 2014 ; 16 (4) : 330-335.

ISSN 2336-288x
Medvik
Zdroj

Hluboká žilní trombóza spolu s potenciální komplikací – plicní embolizací – se vyskytuje u více než 100 nemocných na 100 000 obyvatel. Její incidence se v posledních 25 letech nemění. Většina případů je léčena konzervativně, tj. antikoagulancii, přičemž řada nemocných může být léčena i ambulantně. Plejáda léčebných možností se rozšiřuje zavedením nových přímých orálních antikoagulancií s praktickými výhodami podání. V současnosti máme možnost užití klasické překryvné léčby kombinací nízkomolekulárního heparinu s warfarinem, nově také přechodu z LMWH na dabigatran nebo léčíme od prvého dne pouze perorálně – rivaroxabanem, perspektivně také apixabanem. Pouze malá část nemocných s proximální trombózou je léčena endovaskulárně, nejčastěji lokální farmako‑mechanickou trombolýzou, případně doplněnou o implantaci stentu. Chirurgická trombektomie je metodou volby u čerstvé trombózy při nemožnosti užití antitrombotika. Kavální filtry jako prevence plicní embolie jsou zaváděny řídce, v přísně specifikovaných situacích.

The annual incidence of deep vein thrombosis (DVT) together with possible complications – pulmonary embolization – is more than 100 per 100,000 person‑years and has not changed significantly over the last 25 years. Most cases of DVT are treated conservatively with anticoagulants, which can often be given in an outpatient setting. The list of treatment modalities has enlarged recently – new direct oral anticoagulants (NOACs) have been introduced, with practical advantages. At present, it is possible to use the traditional overlap schedule with low molecular weight heparin (LMWH) and warfarin or dabigatran. A more convenient strategy comprises oral treatment only, from the time of diagnosis, with rivaroxaban or apixaban, respectively. Only a minority of well‑selected patients with proximal thrombosis is treated using pharmaco‑mechanical lysis, in some cases with the necessity of stent implantation into the iliac vein. Surgical removal of the clot is the method of choice only in fresh thrombosis when no antithrombotic drug can be administered. Vena cava filters for the prevention of pulmonary embolization are inserted infrequently, in strictly specified situations.

Článek

Tromboembolizační příčiny iktů aneb Léčíme tromboembolii dostatečně?

Kongresový list. 2014 ; 2014 (6) : 66-68.

Medvik
Zdroj

MeSH
antikoagulancia * škodlivé účinky terapeutické užití MeSH
cévní mozková příhoda * epidemiologie etiologie MeSH
chemoprofylaxe metody MeSH
faktor Xa terapeutické užití MeSH
hodnocení rizik MeSH
inhibitory faktoru Xa MeSH
komorbidita MeSH
kongresy jako téma MeSH
krvácení chemicky indukované prevence a kontrola MeSH
lidé MeSH
senioři MeSH
tromboembolie * farmakoterapie prevence a kontrola MeSH
věkové faktory MeSH
Check Tag
lidé MeSH
mužské pohlaví MeSH
senioři MeSH
ženské pohlaví MeSH
Publikační typ
kazuistiky MeSH

Článek

Jak zvýšit adherenci k antikoagulační léčbě

Chlumský, Jaromír, 1962-
Autor Autorita Interní klinika 2. LF UK a FN Motol

Medical tribune. 2014 ; 10 (9) : B2, B4.

Med. Trib. (Praha)
ISSN 1214-8911
Medvik
Zdroj

Kolekce

Publikováno

Filtry

* Zobrazit nápovědu

* Zobrazit nápovědu

Upřesnit dle MeSH